Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $30.55.

ROIV has been the subject of a number of analyst reports. Piper Sandler increased their price target on Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday. HC Wainwright increased their price target on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Guggenheim increased their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $29.83 on Wednesday. Roivant Sciences has a 52-week low of $10.01 and a 52-week high of $30.33. The firm has a market capitalization of $21.35 billion, a PE ratio of -25.50 and a beta of 1.20. The stock has a fifty day simple moving average of $28.07 and a two-hundred day simple moving average of $23.24.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares of the company’s stock, valued at $506,865,136.08. This represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director owned 15,804 shares of the company’s stock, valued at $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 4,595,624 shares of company stock worth $124,848,136. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley raised its position in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP raised its position in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares in the last quarter. State Street Corp raised its position in shares of Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares in the last quarter. Finally, UBS Group AG raised its position in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.